Abstract
Matrix metalloproteinase-9 (MMP-9) which is a member of matrix metalloproteinases family that normally remodel the extracellular matrix, has been shown to play an important role in both animal models of cerebral ischemia and human stroke. The expression of MMP-9 is elevated after cerebral ischemia which is involved in accelerating matrix degradation, disrupting the blood-brain barrier, increasing the infarct size and relating to hemorrhagic transformation. Recently, many drugs, such as tetracycline derivatives, cyclooxygenase inhibitors, ACEI inhibitors and AT1 receptor blockers, etc., have been found to attenuate the elevated expression levels of MMP-9 after ischemia and to reduce the damage of cerebral ischemic. This article reviews the physiological features of MMP-9 and its important role in the genesis, propagation, and therapeutics of cerebral ischemic diseases.
Keywords: Matrix metalloproteinase-9 (MMP-9), cerebral ischemia, regulation, therapeutical target
Current Neuropharmacology
Title: MMP-9, a Potential Target for Cerebral Ischemic Treatment
Volume: 7 Issue: 4
Author(s): Xue Dong, Yu-Ning Song, Wei-Guo Liu and Xiu-Li Guo
Affiliation:
Keywords: Matrix metalloproteinase-9 (MMP-9), cerebral ischemia, regulation, therapeutical target
Abstract: Matrix metalloproteinase-9 (MMP-9) which is a member of matrix metalloproteinases family that normally remodel the extracellular matrix, has been shown to play an important role in both animal models of cerebral ischemia and human stroke. The expression of MMP-9 is elevated after cerebral ischemia which is involved in accelerating matrix degradation, disrupting the blood-brain barrier, increasing the infarct size and relating to hemorrhagic transformation. Recently, many drugs, such as tetracycline derivatives, cyclooxygenase inhibitors, ACEI inhibitors and AT1 receptor blockers, etc., have been found to attenuate the elevated expression levels of MMP-9 after ischemia and to reduce the damage of cerebral ischemic. This article reviews the physiological features of MMP-9 and its important role in the genesis, propagation, and therapeutics of cerebral ischemic diseases.
Export Options
About this article
Cite this article as:
Dong Xue, Song Yu-Ning, Liu Wei-Guo and Guo Xiu-Li, MMP-9, a Potential Target for Cerebral Ischemic Treatment, Current Neuropharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157015909790031157
DOI https://dx.doi.org/10.2174/157015909790031157 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases
Current Medicinal Chemistry The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Wound Healing Effects of Curcumin: A Short Review
Current Pharmaceutical Biotechnology Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Development of New Fibrinolytic Agents
Current Pharmaceutical Design The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Magnetic Resonance Perfusion Imaging Provides a Significant Tool for the Identification of Cardioembolic Stroke
Current Neurovascular Research Attenuation of Microvascular Injury in Preconditioned Ischemic Myocardium: Imaging with Tc-99m Glucaric Acid and In-111 Human Fibrinogen
Current Molecular Imaging (Discontinued) Simultaneous Separation, Quantitation, and Determination of the Dissociation Constant of Five Components of Ixeris sonchifolia by Microemulsion Electrokinetic Chromatography
Current Pharmaceutical Analysis Protective Effects of Astragalus Membranaceus and Ligustrazine on Rat Brain Microvascular Endothelial Cell Injury after Oxygen-Glucose Deprivation/ Reoxygenation by Suppressing the PKCδ/MARCKS Pathway
Combinatorial Chemistry & High Throughput Screening Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk
Current Medicinal Chemistry Brown Recluse Spider Venom: Proteomic Analysis and Proposal of a Putative Mechanism of Action
Protein & Peptide Letters Hsp20 Protects Neuroblastoma Cells from Ischemia/Reperfusion Injury by Inhibition of Apoptosis via a Mechanism that Involves the Mitochondrial Pathways
Current Neurovascular Research Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets